RxDoctor Payments Data

Kimberlee Sartain, APRN

Psychiatric/Mental Health · Barling, ARNPI 1619487733

Payments from drug & device makers

$2,170in general payments, 2019–2025

Across 60 payments — averaging $36.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$428
  • Axsome Therapeutics, Inc.$358
  • AbbVie$294
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$219
  • Teva Pharmaceuticals USA, Inc.$182
  • Takeda Pharmaceuticals U.S.A., Inc.$181
  • plus $509 from 8 others

What the payments were for

  • Food & beverage$2,170100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,170 in reported general payments places this provider in the 75th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$30,271
Medicare patients
72
Services billed
361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole22$33,357
TrintellixVortioxetine Hydrobromide23$18,100
Nefazodone Hcl12$1,899
Bupropion XlBupropion Hcl60$1,129
Aripiprazole25$787
Doxepin Hcl16$620
Clonazepam105$527
Lamotrigine75$487
Prazosin Hcl21$420
Buspirone Hcl32$371
Escitalopram Oxalate63$331
Hydroxyzine Hcl19$309
Venlafaxine Hcl ErVenlafaxine Hcl25$283
Sertraline Hcl58$277
Duloxetine Hcl27$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$428$33,35722 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$181$18,10023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Barling

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →